Upcoming readouts, next 12 months

D-1553 Tablet Versus Docetaxel Injection for KRAS G12C Mutation-positive Locally Advanced or Metastatic Non-small Cell Lung Cancer After Prior Standard Therapy Failure

KRAS G12C Chia Tai Tianqing (Sino Biopharm) garsorasib NCT06300177

A Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab) in Patients With Advanced or Metastatic Melanoma

BRAF V600E Pfizer encorafenib, binimetinib, pembrolizumab NCT04657991

Capivasertib+Fulvestrant asTreatment for Locally Advanced(Inoperable) or Metastatic HR+/HER2- Breast Cancer in Chinese Patients

PIK3CA activating mutation AstraZeneca capivasertib, fulvestrant NCT06635447

Study to Evaluate Efficacy & Safety of Afuresertib Plus Fulvestrant in Patients With Locally Advanced or Metastatic HR+/HER2- Breast Cancer

PIK3CA activating mutation Laekna afuresertib, fulvestrant NCT04851613

Vebreltinib Plus PLB1004 as the First-line Therapy for Patients With EGFRm+/MET+ Locally Advanced or Metastatic NSCLC.

EGFR exon 19 deletion / L858R Avistone Biotechnology vebreltinib, osimertinib, PLB1004 NCT06574347

Primary Tumor Resection With EGFR TKI for Stage IV NSCLC

EGFR exon 19 deletion / L858R National Taiwan University Hospital afatinib NCT05215548

Osimertinib and Gefitinib in EGFR Inhibitor naïve Advanced EGFR Mutant Lung Cancer

EGFR exon 19 deletion / L858R Dana-Farber Cancer Institute gefitinib, osimertinib NCT03122717

A Phase Ib/II Clinical Study to Evaluate HLX43 in Combination With Serplulimab in Patients With Advanced/Metastatic Solid Tumors

EGFR exon 19 deletion / L858R Henlius HLX43, serplulimab NCT06848699

A Study of TAK-788 in Adults With Non-Small Cell Lung Cancer

EGFR exon 19 deletion / L858REGFR exon 20 insertionHER2 (ERBB2) activating mutation Takeda mobocertinib NCT02716116

Trial of Two Adagrasib Dosing Regimens in NSCLC With KRAS G12C Mutation (KRYSTAL 21)

KRAS G12C Bristol Myers Squibb adagrasib NCT05853575

STREAM-2: Second-line Treatment With REgorafenib in Advanced RAS-Mutant Colorectal Cancer

KRAS G12CKRAS G12D National Cancer Institute, Naples standard second line treatment, at discretion of the investigator, regorafenib NCT07213570

A Study of TSN1611 Treating Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation

KRAS G12D Tyligand Pharmaceuticals TSN1611 NCT06385925

Laser Ablation of Papillary Thyroid Microcarcinoma

BRAF V600E Memorial Sloan Kettering Cancer Center NCT04623801

Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients

BRAF V600E Vyriad VV1, cemiplimab NCT04291105

A Study Evaluating the Activity of Anti-cancer Treatments Targeting Tumor Molecular Alterations/Characteristics in Advanced / Metastatic Tumors.

BRAF V600EALK fusionROS1 fusionNTRK1/2/3 fusion Centre Leon Berard siremadlin, ribociclib, cabozantinib, alectinib NCT04116541

Study Investigating the Efficacy and Safety of the Addition of Oral-azacitidine to Salvage Treatment by Gilteritinib in Subjects ≥18 Years of Age With Relapsed/Refractory FLT3-mutated Acute Myeloid Leukemia

FLT3 mutation (ITD/TKD) French Innovative Leukemia Organisation gilteritinib NCT06022003

Combination of QLS31905 and Chemotherapy ± QL2107 in Patients With CLDN18.2-positive Advanced Biliary Tract Cancer

Claudin 18.2 expression Qilu Pharmaceutical QLS31905, QL2107 Injection NCT07151872

A Study of Zolbetuximab (IMAB362) in Adults With Pancreatic Cancer

Claudin 18.2 expression Astellas zolbetuximab NCT03816163

TL938 and Trastuzumab for Patients With HER2-positive Metastatic Colorectal Cancer

MSI-H / dMMR Teligene TL938 Capsules, trastuzumab NCT06589830

Nous-209 Genetic Vaccine for the Treatment of Microsatellite Unstable Solid Tumors

MSI-H / dMMR Nouscom GAd-209-FSP low dose, MVA-209, GAd-209-FSP high dose, GAd20-209-FSP, RP2D NCT04041310

A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy

PIK3CA activating mutation Roche inavolisib, fulvestrant, alpelisib, Bupropion NCT05646862

Pharmacogenomics IND SNP Clinical Trial - Alectinib and Single Nucleotide Polymorphisms

ALK fusion Medicine Invention Design alectinib NCT05987956

LM-302 for the Treatment of Subjects With Claudin18.2-Positive Gastric and Gastroesophageal Junction Adenocarcinoma.

Claudin 18.2 expression LaNova Medicines Zhejiang LM-302, apatinib NCT06351020

Andamertinib With or Without Platinum-doublet Chemotherapy Versus Platinum-doublet Chemotherapy in Patients With NSCLC Harboring Atypical EGFR Mutations

EGFR exon 19 deletion / L858R Avistone Biotechnology PLB1004 NCT07336732

A Study of SYS6010 Combined With Osimertinib Versus Osimertinib Alone as Neoadjuvant Therapy for Patients With EGFR Mutation-positive Resectable Non-squamous Non-small Cell Lung Cancer

EGFR exon 19 deletion / L858R CSPC SYS6010, osimertinib NCT07256509

Tiragolumab With Atezolizumab Plus Bevacizumab in Previously-Treated Advanced Non-squamous NSCLC

EGFR exon 19 deletion / L858R Georgetown University tiragolumab, atezolizumab, bevacizumab NCT04958811

A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)

KRAS G12CBRAF V600EALK fusionROS1 fusionRET fusion or mutationNTRK1/2/3 fusion Roche alectinib, entrectinib, vemurafenib, cobimetinib NCT04302025

Study of Onvansertib in Combination With FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab Versus FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab for First-Line Treatment of Metastatic Colorectal Cancer in Adult Participants With a KRAS or NRAS Mutation

KRAS G12CKRAS G12D Cardiff Oncology Onvansertib, bevacizumab NCT06106308

To Evaluate the Safety and Efficacy of RNK08954 in Patients With Metastatic Pancreatic Ductal Adenocarcinoma.

KRAS G12D Ranok Therapeutics RNK08954 NCT07303465

A Study to Evaluate ARV-806 in Adults With Advanced Cancer That Has the KRAS G12D Mutation

KRAS G12D Arvinas ARV-806 NCT07023731

Vemurafenib and Cobimetinib for the Treatment of Patients With High Risk Differentiated Thyroid Carcinoma With BRAFV600E Mutation

BRAF V600E City of Hope Medical Center cobimetinib, Recombinant Thyrotropin Alfa, vemurafenib NCT06440850

Pembrolizumab in High-risk Thyroid Cancer

BRAF V600E Istituti Clinici Scientifici Maugeri SpA pembrolizumab NCT05852223

Phase 1b/2 Study to Evaluate ABT-101 in Solid Tumor and NSCLC Patients

HER2 (ERBB2) activating mutation Anbogen Therapeutics ABT-101 NCT05532696

Mirvetuximab Soravtansine (MIRV) With Carboplatin in Second-line Treatment of Folate Receptor Alpha (FRα) Expressing, Platinum-sensitive Epithelial Ovarian Cancer

BRCA1/2 mutation AbbVie Mirvetuximab soravtansine NCT05456685

Safety and Efficacy Study in Recurrent or Progressive Grade III or IV IDH1 Mutated Glioma

IDH1/2 mutation Neonc Technologies Perillyl alcohol NCT02704858

Study of Intensity Modulated Total Marrow Irradiation (IM-TMI) in Addition to Fludarabine/Busulfan Conditioning for Allogeneic Transplantation in High Risk AML and Myelodysplastic Syndromes

FLT3 mutation (ITD/TKD) University of Illinois at Chicago Busulfan, ATG NCT03121014

Safety and Preliminary Anti-Tumor Activity of TYRA-300 in Advanced Urothelial Carcinoma and Other Solid Tumors With FGFR3 Gene Alterations

FGFR3 alteration (mutation or fusion) Tyra Biosciences TYRA-300 NCT05544552

Pembrolizumab Plus Bevacizumab and Chemotherapy for ALK-rearranged NSCLC With Persistent 5'ALK

ALK fusion Hunan Province Tumor Hospital pembrolizumab, bevacizumab NCT05266846

Clinical Utility of Liquid Biopsy in Brigatinib ALK+ Patients

ALK fusion Fundación GECP brigatinib NCT04223596

T-DXd Therapy for HER2-low Breast Cancer Patients With Brain Metastases

HER2-low / ultralow (IHC 1+ or 2+/ISH-) MedSIR trastuzumab deruxtecan NCT06048718

AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2

Claudin 18.2 expression AstraZeneca AZD0901 NCT06219941

Single-arm, Phase II Clinical Study Evaluating the Safety and Efficacy of Sintilimab Combined With IBI-310 and Chemotherapy as Neoadjuvant Therapy for Locally Advanced Rectal Cancer

MSI-H / dMMR Xijing Hospital NCT07750951

A Phase IIa Randomized, Double-Blinded Clinical Trial of Naproxen or Aspirin for Cancer Immune Interception in Lynch Syndrome

MSI-H / dMMR M.D. Anderson Cancer Center Naproxen NCT05411718

A Study of Dostarlimab in Untreated dMMR/MSI-H Locally Advanced Rectal Cancer

MSI-H / dMMR GSK dostarlimab NCT05723562

Study of Induction PD-1 Blockade in Subjects With Locally Advanced Mismatch Repair Deficient Solid Tumors

MSI-H / dMMR Memorial Sloan Kettering Cancer Center dostarlimab NCT04165772

Tislelizumab (Anti-Programmed Cell Death Protein-1 (PD-1) Antibody) in MSI-H or dMMR Solid Tumors

MSI-H / dMMR BeOne Medicines (BeiGene) tislelizumab NCT03736889

A Phase Ⅲ Clinical Study of SYS6010 in Combination With Osimertinib in Patients With Locally Advanced or Metastatic NSCLC

EGFR exon 19 deletion / L858R CSPC SYS6010, osimertinib NCT07376382

Furmonertinib 160mg as First-line Treatment in Locally Advanced or Metastatic NSCLC With EGFR Classical Mutations

EGFR exon 19 deletion / L858R Peking Union Medical College Hospital furmonertinib NCT06674343

MDT-bridged Radical Therapy After Aumolertinib With MRD-guided Maintenance in EGFRm+ Unresectable Stage III NSCLC (APPROACH)

EGFR exon 19 deletion / L858R Guangdong Association of Clinical Trials aumolertinib NCT04841811

To Assess the Efficacy and Safety of Furmonertinib Versus Placebo, in Patients With Epidermal Growth Factor Receptor Mutation Positive Stage II-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy

EGFR exon 19 deletion / L858R Allist Pharmaceuticals furmonertinib NCT04853342

A Study of SHR-A2009 Versus Platinum-based Chemotherapy in EGFR-mutated, Advanced or Metastatic NSCLC

EGFR exon 19 deletion / L858R Jiangsu Hengrui SHR-A2009, platinum-based dual-agent chemotherapy NCT06671379

PD-1 Inhibitor and Chemotherapy With Concurrent Irradiation at Varied Tumour Sites in Advanced Non-small Cell Lung Cancer

EGFR exon 19 deletion / L858RALK fusion UNICANCER pembrolizumab NCT03774732

Combination With Sintilimab and XELOX+Bevacizumab as 1st Line Therapy in RAS-mutant Metastatic Colorectal Cancer

KRAS G12CKRAS G12D Second Affiliated Hospital, Zhejiang University, School of Medicine sintilimab, bevacizumab NCT05171660

Efficacy and Safety of Tunlametinib Plus Vemurafenib in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer

BRAF V600E Shanghai Kechow Pharma vemurafenib, bevacizumab, cetuximab NCT06008119

ESTIMation of the ABiLity of Prophylactic Central Compartment Neck Dissection to Modify Outcomes in Low-risk Differentiated Thyroid Cancer

BRAF V600E Gustave Roussy, Cancer Campus, Grand Paris NCT03570021

A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer

PIK3CA activating mutation Roche inavolisib, Phesgo, Taxane-based Chemotherapy, Optional Endocrine Therapy of Investigator's Choice NCT05894239

Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment

HER2 (ERBB2) activating mutation Boehringer Ingelheim zongertinib, pembrolizumab NCT06151574

A Clinical Study of TQB3454 Tablets in the Treatment of Advanced Biliary Carcinoma.

IDH1/2 mutation Chia Tai Tianqing (Sino Biopharm) TQB3454 tablets, TQB3454 tablets matching placebo NCT05987358

Study of Tinengotinib VS. Physician's Choice a Treatment of Subjects With FGFR-altered in Cholangiocarcinoma

FGFR3 alteration (mutation or fusion)FGFR2 fusion or rearrangement TransThera Sciences tinengotinib, Physician's Choice NCT05948475

ASKB589 in Combination With CAPOX and PD-1 Inhibitor in Patients With Advanced or Metastatic GC/GEJ Adenocarcinoma

Claudin 18.2 expression AskGene Pharma ASKB589, tislelizumab NCT06206733

A Multicenter, Phase 3 Study of IBI343 Monotherapy Versus Treatment of Investigator's Choice in Subjects With Previously Treated, Claudin (CLDN) 18.2-positive, HER2-negative, Gastric or Gastroesophageal Junction Adenocarcinoma (G-HOPE-001)

Claudin 18.2 expression Innovent Biologics IBI343 NCT06238843

Identification and Treatment Of Micrometastatic Disease in Stage III Colon Cancer

MSI-H / dMMR Massachusetts General Hospital nivolumab, encorafenib, binimetinib, cetuximab NCT03803553

A Clinical Study on the Efficacy and Safety of the Combination of Limertinib and Bevacizumab Versus Limertinib as First-line Treatment for NSCLC.

EGFR exon 19 deletion / L858R Shanghai Chest Hospital limertinib, bevacizumab NCT06982924

ORIENT-31 Regimen in Combination With SBRT for EGFR-mutant Metastatic NSCLC After First-line Third-generation EGFR-TKIs

EGFR exon 19 deletion / L858R Fudan University ORIENT-31 regimen NCT06775743

Firmonertinib Combined With Chemotherapy as Neoadjuvant Therapy for Resectable Stage Ⅱ-ⅢB EGFR Sensitive Mutanted NSCLC

EGFR exon 19 deletion / L858R Tianjin Medical University Cancer Institute and Hospital furmonertinib NCT06890182

Necitumumab and Trastuzumab in Combination With Osimertinib for the Treatment of Refractory Epidermal Growth Factor Receptor (EGFR)-Mutated Stage IV Non-small Cell Lung Cancer

EGFR exon 19 deletion / L858R Jonsson Comprehensive Cancer Center necitumumab, osimertinib, trastuzumab NCT04285671

Phase II Randomized Trial of Carboplatin+Pemetrexed+Bevacizumab+/- Atezolizumab in Stage IV NSCLC

EGFR exon 19 deletion / L858R Fox Chase Cancer Center Arm A, Arm B NCT03786692

Study of Osimertinib With and Without Ramucirumab in Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

EGFR exon 19 deletion / L858R Xiuning Le osimertinib, ramucirumab NCT03909334

Osimertinib Combined With Savolitinib in the Treatment of NSCLC With Low Copy Number MET Amplification

EGFR exon 19 deletion / L858R Qingdao Central Hospital savolitinib, osimertinib NCT07322783

High-dose Furmonertinib or Combined With Chemotherapy in EGFR-mutant Advanced NSCLC After Disease Progression on Third-generation EGFR-TKI

EGFR exon 19 deletion / L858R Jialei Wang furmonertinib NCT06652048

Efficacy and Safety of T-DXd in HER2-mutant Advanced Lung Cancer Patients With Asymptomatic Brain Metastases

EGFR exon 19 deletion / L858RHER2 (ERBB2) activating mutation Yonsei University trastuzumab deruxtecan NCT06250777

Intrathecal Pemetrexed for Leptomeningeal Metastasis in EGFR-Mutant NSCLC

EGFR exon 19 deletion / L858R Taipei Veterans General Hospital, Taiwan NCT05805631

Efficacy and Resistance Mechanisms of IP in NSCLC With Leptomeningeal Metastases

EGFR exon 19 deletion / L858RKRAS G12CKRAS G12DBRAF V600EALK fusionROS1 fusionRET fusion or mutationNTRK1/2/3 fusion Hunan Province Tumor Hospital NCT06440954

High-dose Furmonertinib Versus Osimertinib in Advanced EGFRm NSCLC Patients With Brain Metastases

EGFR exon 19 deletion / L858R Taizhou Hospital furmonertinib, osimertinib NCT06319950

Vebreltinib Plus PLB1004 in EGFR-mutated, Advanced NSCLC With MET Amplification or MET Overexpression Following EGFR-TKI

EGFR exon 19 deletion / L858R Avistone Biotechnology vebreltinib, PLB1004 NCT06343064

The Efficacy and Safety of IBI363 in Solid Tumors

EGFR exon 19 deletion / L858RALK fusionRET fusion or mutation Hunan Province Tumor Hospital IBI363, lenvatinib NCT06081907

Pemetrexed and Carboplatin With or Without Anlotinib Hydrochloride for Osimertinib-resistant Non-squamous NSCLC

EGFR exon 19 deletion / L858R Fudan University anlotinib NCT04136535

Targeted Treatment for RET Fusion-Positive Advanced Non-Small Cell Lung Cancer (A LUNG-MAP Treatment Trial)

EGFR exon 19 deletion / L858RBRAF V600EMET exon 14 skippingALK fusionROS1 fusionRET fusion or mutation SWOG Cancer Research Network selpercatinib NCT04268550

Perioperative Treatment of Sunvozertinib in Stage II-IIIB NSCLC

EGFR exon 20 insertion Tang-Du Hospital sunvozertinib NCT06864624

Phase 2 Clinical Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of GH21 Capsules Combined With D-1553 Tablets in Subjects With Locally Advanced or Metastatic Solid Tumors With the KRASG12C Mutation

KRAS G12C Suzhou Genhouse Bio garsorasib NCT07318649

A Phase II Study Evaluating JAB-21822 Monotherapy in Adult Patients With Pancreatic Cancer and Other Solid Tumors Harboring the KRAS p.G12C Mutation.

KRAS G12C Allist Pharmaceuticals glecirasib NCT06008288

Testing the Use of Targeted Treatment (AMG 510) for KRAS G12C Mutated Advanced Non-squamous Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)

KRAS G12C SWOG Cancer Research Network sotorasib NCT04625647

Iparomlimab/Tuvonralimab Combined With Bevacizumab and CAPEOX as Conversion Therapy for Colorectal Cancer Liver Metastasis

KRAS G12CKRAS G12D Peking University Cancer Hospital & Institute Iparomlimab/Tuvonralimab, bevacizumab NCT07007728

Phase 1/2 Study of HYP-2090PTSA in Patients With Advanced Solid Tumors Harboring KRAS Mutation

KRAS G12CKRAS G12D Sichuan Huiyu Pharmaceutical Test product: HYP-2090PTSA NCT06243354

A Phase I/IIa Study of JAB-23E73 in Patients With Advanced Solid Tumors Harboring KRAS Gene Alteration

KRAS G12CKRAS G12D Jacobio Pharmaceuticals JAB-23E73 NCT06959615

FOLFOX Via HAI Plus Intravenous Irinotecan With or Without Bevacizumab Versus Systemic FOLFOXIRI With or Without Bevacizumab in Initially Unresectable RAS-mutated CRLM Patients

KRAS G12CKRAS G12DBRAF V600E Sun Yat-sen University bevacizumab NCT05727163

Testing the Combination of the Anti-cancer Drugs ZEN003694 (ZEN-3694) and Talazoparib in Patients With Advanced Solid Tumors, The ComBET Trial

KRAS G12CKRAS G12DBRCA1/2 mutation National Cancer Institute (NCI) ZEN-3694, talazoparib NCT05327010

Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML

KRAS G12CKRAS G12D Sellas Life Sciences Group SLS009, venetoclax NCT04588922

A Study of RNK08954 in Subjects With Advanced Solid Tumors With KRAS ((Kirsten Rat Sarcoma) G12D Mutation

KRAS G12D Ranok Therapeutics RNK08954-01 NCT06667544

Irinotecan Liposomes Combined with Cetuximab + Vermofenib in First-line Failure of Advanced Colorectal Cancer

BRAF V600EMSI-H / dMMR Fudan University cetuximab NCT06763029

Encorafenib Plus Cetuximab in a Neoadjuvant Setting in Patients With BRAF Mutation Localised Colon or Upper Rectum Cancer

BRAF V600E Federation Francophone de Cancerologie Digestive encorafenib, cetuximab NCT05706779

Clinical Study of Neoadjuvant Targeted Therapy for Ameloblastoma

BRAF V600E Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University dabrafenib, trametinib NCT06653517

KN 046 Plus Regorafenib in MSS Metastatic Colorectal Cancer

BRAF V600E Peking University Cancer Hospital & Institute KN046, regorafenib NCT05985109

Safety and Tolerability Study of GIM-531 in Advanced Solid Tumors

BRAF V600E Georgiamune GIM-531, Anti-PD-1 monoclonal antibody NCT06425926

Potential of Moderate Whole Body Hyperthermia to Enhance Response

BRAF V600E Charite University, Berlin, Germany NCT05821166

A Clinical Trial of Regorafenib in Patients With Pretreated Advanced Melanoma

BRAF V600E Universitair Ziekenhuis Brussel regorafenib, Triplet therapy NCT05370807

A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors

BRAF V600E Sapience Therapeutics ST101 NCT04478279

A Phase II, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of Neoadjuvant Therapy With Inavolisib Plus Pertuzumab and Trastuzumab as Subcutaneous (PH-FDC SC) and 3-week Cycle Nab-paclitaxel for PIK3CA-mutated, HER2+, eBC

PIK3CA activating mutation Zhimin Shao pertuzumab, trastuzumab, inavolisib NCT07245797

Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Participants With Metastatic Breast Cancer

PIK3CA activating mutation Stemline Therapeutics elacestrant, alpelisib, everolimus, ribociclib NCT05563220

Evexomostat Plus PI3K or AKT Inhibitor and Fulvestrant in Patients With a PI3K Alteration and HR+/Her2- Breast Cancer

PIK3CA activating mutation SynDevRx Evexomostat NCT05455619

Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmocodynamics and Preliminary Antitumor Activity of AT-1965 in Patients With Advanced, Refractory or Recurrent Solid Tumors

BRCA1/2 mutation Alyssum Therapeutics AT-1965 Liposome Injection NCT06234098

Niraparib in Tumors Metastatic to the CNS

BRCA1/2 mutation Massachusetts General Hospital niraparib NCT04992013

Adavosertib With or Without Olaparib in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

BRCA1/2 mutation M.D. Anderson Cancer Center adavosertib, olaparib, ceralasertib NCT03579316

Talazoparib in Treating Patients With Recurrent, Refractory, Advanced, or Metastatic Cancers and Alterations in the BRCA Genes

BRCA1/2 mutation M.D. Anderson Cancer Center talazoparib NCT02286687

Niraparib and Temozolomide in Patients Glioblastoma

IDH1/2 mutation Armando Santoro, MD niraparib NCT06258018

AlloSCT for Malignant and Non-malignant Hematologic Diseases Utilizing Alpha/Beta T Cell and CD19+ B Cell Depletion

FLT3 mutation (ITD/TKD) Mitchell Cairo alpha beta depletion NCT04099966

A Study of BN104 in the Treatment of Acute Leukemia

NPM1 mutation Institut de Recherches Internationales Servier (I.R.I.S.) BN104 monotherapy, BN104 monotherapy - rp2d NCT06052813

A Phase I-II Study Investigating the All-Oral Combination of the Menin Inhibitor SNDX-5613 With Decitabine/Cedazuridine (ASTX727) and Venetoclax in Acute Myeloid Leukemia (SAVE)

NPM1 mutation M.D. Anderson Cancer Center revumenib, venetoclax NCT05360160

Ensartinib in the Treatment of ALK Positive or MET Exon 14 Skipping Anvanced Solid Tumors Excluded Lung Cancer

MET exon 14 skippingALK fusion Nanjing First Hospital, Nanjing Medical University ensartinib NCT06762327

A Study of LP-300 With Carboplatin and Pemetrexed in Never Smokers With Advanced Lung Adenocarcinoma

MET exon 14 skippingNTRK1/2/3 fusion Lantern Pharma LP-300 NCT05456256

A Phase II Nationwide, Fully Decentralized, Telemedicine Study of Pemigatinib in Adult Patients With Advanced or Metastatic Pancreatic Cancer With FGFR Genetic Alterations

FGFR3 alteration (mutation or fusion)FGFR2 fusion or rearrangement Sameek Roychowdhury pemigatinib NCT06906562

Mitoxantrone Hydrochloride Liposome and Enlonstobart Combination Treatment in Patients With Relapsed or Refractory Peripheral T Cell Lymphoma (PTCL)

ALK fusion Sun Yat-Sen University Cancer Center NCT07288814

Alectinib Pharmacokinetic in Patients With NSCLC

ALK fusion Instituto Nacional de Cancerologia de Mexico alectinib NCT05713006

The Efficacy and Safety of LMV-12 Combined With Osimertinib in NSCLC

RET fusion or mutation Hunan Province Tumor Hospital osimertinib NCT06109558

A Study of KL590586 in Patients With Advanced Solid Tumors

RET fusion or mutation Kelun-Biotech KL590586 Capsule NCT05265091

Study of Futibatinib in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusion or Rearrangement

FGFR2 fusion or rearrangement Taiho Pharmaceutical futibatinib NCT05727176

A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion (eNRGy)

NRG1 fusion Partner Therapeutics zenocutuzumab NCT02912949

Disitamab Vedotin Plus Bevacizumab in HER2-Low Metastatic Breast Cancer After T-DXd Failure: A Phase II Study

HER2-low / ultralow (IHC 1+ or 2+/ISH-) The First Affiliated Hospital with Nanjing Medical University disitamab vedotin, bevacizumab NCT07446452

A Phase II Study of Advanced Salivary Gland Carcinoma Based on Molecular Typing

HER2-low / ultralow (IHC 1+ or 2+/ISH-) Fudan University trastuzumab rezetecan, SHR 3680 + leuprolide, SHR-A1921 NCT05924256

Trastuzumab Deruxtecan Alone or in Combination With Anastrozole for the Treatment of Early Stage HER2 Low, Hormone Receptor Positive Breast Cancer

HER2-low / ultralow (IHC 1+ or 2+/ISH-) Jonsson Comprehensive Cancer Center anastrozole, trastuzumab deruxtecan NCT04553770

Combination of QLS31905, QL2107 and Chemotherapy as First-line Therapy in CLDN18.2-positive Unresectable Locally Advanced or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

Claudin 18.2 expression Qilu Pharmaceutical QLS31905, QL2107 Injection NCT06942767

XNW27011 Study of Advanced Solid Tumor Subjects Who Failed Standard Therapies.

Claudin 18.2 expression Astellas XNW27011 NCT06792435

Psilocybin-Assisted Psychotherapy in Patients With Advanced Cancer on Maintenance Therapy

MSI-H / dMMR M.D. Anderson Cancer Center Psilocybin NCT06200155

AK104 in Locally Advanced MSI-H/dMMR Gastric Carcinoma and Colorectal Cancer

MSI-H / dMMR Peking University cadonilimab NCT04556253

KN046 Plus Regorafenib or Apatinib in MSI-H Digestive System Cancers Resistant to PD-1/PD-L1 Blockade

MSI-H / dMMR Peking University Cancer Hospital & Institute KN046, regorafenib, apatinib NCT06099821

KN035 for dMMR/MSI-H Advanced Solid Tumors

MSI-H / dMMR 3D Medicines KN035 NCT03667170

Oral Azacitidine in Transplant-Eligible Patients With Acute Myeloid Leukemia (AML) Suffering From Health-Inequality

FLT3 mutation (ITD/TKD) Virginia Commonwealth University NCT06370000

A Study to Evaluate the Safety of Dostarlimab in Adult Participants in India With Recurrent or Advanced Endometrial Cancer (EC)

MSI-H / dMMR GSK dostarlimab NCT06897527

A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer

EGFR exon 19 deletion / L858R AstraZeneca datopotamab deruxtecan, osimertinib NCT06417814

Study to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant in Participants With HR-positive (HR+), HER2-negative, Advanced Breast Cancer After Treatment With a CDK4/6 Inhibitor and an Aromatase Inhibitor.

PIK3CA activating mutation Novartis alpelisib, fulvestrant NCT05038735

A Clinical Trial of TQB2102 for Injection in the Treatment of HER2 Low-Expressing Recurrent/Metastatic Breast Cancer

HER2-low / ultralow (IHC 1+ or 2+/ISH-) Chia Tai Tianqing (Sino Biopharm) TQB2102 for Injection NCT06561607

High-Dose Firmonertinib Combined With Bevacizumab and Intrathecal Pemetrexed in the Treatment of EGFR-Mutated Non-Small Cell Lung Cancer With Leptomeningeal Metastasis

EGFR exon 19 deletion / L858REGFR exon 20 insertion Qiming Wang Combination therapy prospective cohort NCT06971406

Aumolertinib Versus Osimertinib As First-line Therapy for Patients with EGFR Mutated Locally Advanced or Metastatic Non-small-cell Lung Cancer

EGFR exon 19 deletion / L858R Peking Union Medical College Hospital aumolertinib, osimertinib NCT06752408

A Study of Combination Therapy With Amivantamab and Cetrelimab in Participants With Metastatic Non-small Cell Lung Cancer

EGFR exon 19 deletion / L858R Johnson & Johnson Cetrelimab, amivantamab NCT05908734

A Study of YL201 and Ivonescimab (AK112) in Advanced Solid Tumors

EGFR exon 19 deletion / L858R MediLink Therapeutics YL201, ivonescimab NCT07208773

Neoadjuvant Toripalimab for Clinically Stage II-IIIB Resectable Non-small Cell Lung Cancer with EGFR Mutation and PD-L1 Positive Expression

EGFR exon 19 deletion / L858R Ruijin Hospital toripalimab NCT06269211

Safety and Efficacy of Combining APL-101 With Frontline Osimertinib in Patients With EGFR-mutated Metastatic Non-small Cell Lung Cancer (NSCLC)

EGFR exon 19 deletion / L858R Washington University School of Medicine vebreltinib, osimertinib NCT04743505

Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation

KRAS G12C Novartis opnurasib, batoprotafib, tislelizumab NCT04699188

Panitumumab With or Without Trametinib in Treating Patients With Stage IV Colorectal Cancer

KRAS G12CKRAS G12D M.D. Anderson Cancer Center panitumumab, trametinib NCT03087071

NEO- and Adjuvant Targeted Therapy in Braf-mutated Anaplastic Cancer of the Thyroid (NEO-ATACT Study)

BRAF V600E Leiden University Medical Center dabrafenib, trametinib NCT06079333

Neoadjuvant Endocrine Therapy +/- the PI3K Inhibitor Inavolisib in HER2+, HR+, PIK3CA Mutant Early Breast Cancer

PIK3CA activating mutation GBG Forschungs inavolisib, PHESGO, Endocrine therapy NCT05306041

Study Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant Versus Placebo Plus Fulvestrant in Chinese Men and Postmenopausal Women With Advanced Breast Cancer

PIK3CA activating mutation Novartis alpelisib, fulvestrant NCT04544189

A Study of Second Look Laparoscopy (SLL) in People With Ovarian Cancer Who Have Completed Their First Course of Chemotherapy

BRCA1/2 mutation Memorial Sloan Kettering Cancer Center NCT06240598

Pembrolizumab, Olaparib, and Temozolomide for People With Glioma

IDH1/2 mutation Memorial Sloan Kettering Cancer Center pembrolizumab, olaparib NCT05188508

A Study of Azacitidine and Venetoclax in People With Acute Myeloid Leukemia (AML)

NPM1 mutation Memorial Sloan Kettering Cancer Center venetoclax NCT06773208

Savolitinib Combine With Durvalumab in EGFR Wild-type Locally Advanced or Metastatic NSCLC

MET exon 14 skipping AstraZeneca savolitinib, durvalumab NCT05374603

Lorlatinib in ROS1+ NSCLC With Brain Metastasis

ROS1 fusion Hunan Cancer Hospital lorlatinib NCT07083687

Safety and Efficacy of T-DXd vs. CDK4/6i-based ET as First-line Therapy of HR-positive and HER2-low/Ultralow Advanced Breast Cancer Patients Classified as Non-luminal Subtype

HER2-low / ultralow (IHC 1+ or 2+/ISH-) MedSIR trastuzumab deruxtecan, CDK4/6i plus ET NCT06486883

IBI343 Combined With Chemotherapy in Advanced Pancreatic Cancer

Claudin 18.2 expression Zhejiang University IBI343 NCT06770439

Systemic Application of Cadonilimab, LM-302, and S-1 Combined With Intraperitoneal Infusion of Paclitaxel for the Treatment of Claudin 18.2-positive Gastric Cancer With Peritoneal Metastasis

Claudin 18.2 expression Ruijin Hospital cadonilimab, LM-302 NCT06519591

A First-in-human, Dose Escalation and Dose Expansion Study of SAR445877 in Adult Participants With Advanced Solid Tumors

MSI-H / dMMR Sanofi SAR445877, cetuximab, ADG126, bevacizumab NCT05584670

Study of Alpelisib (BYL719) in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy in Patients With HER2-positive Advanced Breast Cancer With a PIK3CA Mutation

PIK3CA activating mutation Novartis alpelisib, trastuzumab, pertuzumab NCT04208178

A Study of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3)

ROS1 fusion Bristol Myers Squibb repotrectinib, crizotinib NCT06140836

Telisotuzumab Vedotin and Osimertinib for the Treatment of Progressive, Incurable, Non Small Cell Lung Cancer

EGFR exon 19 deletion / L858R Jonsson Comprehensive Cancer Center osimertinib, telisotuzumab vedotin NCT07323641

Adagrasib + SRS for Patients With Metastatic KRAS G12C-mutated NSCLC With Untreated Brain Metastases

KRAS G12C Ryan Gentzler, MD adagrasib NCT06248606

SBRT Combined With CAPEOX, Bevacizumab, and PD-1 Inhibitor for the Treatment of RAS-Mutant, MSS-Type, Unresectable Metastatic Colorectal Cancer.

KRAS G12CKRAS G12D The First Affiliated Hospital with Nanjing Medical University PD-1 Inhibitors, bevacizumab NCT06835179

HRS-4642 With Nimotuzumab and Chemotherapy for First-line Treatment of Advanced Pancreatic Cancer Patients

KRAS G12D Zhejiang University HRS-4642, Nimotuzumab NCT06770452

A Single-arm, Single-center, Phase II Clinical Study of Aipalolitovorelizumab (QL1706) Combined With Bevacizumab and Standard Chemotherapy as First-line Treatment for MSS/pMMR Metastatic Colorectal Cancer With BRAF V600E Mutation

BRAF V600E Yanqiao Zhang Aipalolitovorelizumab, bevacizumab NCT07229846

Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer

BRAF V600EALK fusion Aulos Bioscience AU-007, aldesleukin, avelumab, nivolumab NCT05267626

Binimetinib and Encorafenib for the Treatment of Metastatic Melanoma and Central Nervous System Metastases

BRAF V600E M.D. Anderson Cancer Center binimetinib, encorafenib NCT05026983

Study of Efficacy and Safety of LXH254 Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma

BRAF V600E Novartis naporafenib, LTT462, trametinib, ribociclib NCT04417621

Study Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant in Japanese Men and Postmenopausal Women With Advanced Breast Cancer

PIK3CA activating mutation Novartis alpelisib, fulvestrant NCT04524000

A Study of Ocular Toxicity Evaluation and Mitigation During Treatment With Mirvetuximab Soravtansine in Participants With Recurrent Ovarian Cancer With High Folate Receptor-Alpha Expression

BRCA1/2 mutation AbbVie Mirvetuximab Soravtansine, Lubricating Eye Drops, Brimonidine tartrate ophthalmic solution eye drops NCT06365853

Phase 1/2 Clinical Trial of CP-506 (HAP) in Monotherapy or With Carboplatin or ICI

BRCA1/2 mutation Maastricht University Medical Center CP-506, ipilimumab, nivolumab, pembrolizumab NCT04954599

Niraparib With beVAcizumab After Complete cytoreductioN in Patients With ovArian Cancer

BRCA1/2 mutation ARCAGY/ GINECO GROUP Chemotherapy, bevacizumab, niraparib NCT05183984

A Study Comparing Abemaciclib Plus Temozolomide to Temozolomide Monotherapy in Children and Young Adults With High-grade Glioma Following Radiotherapy

IDH1/2 mutation Eli Lilly abemaciclib NCT06413706

Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome

IDH1/2 mutation M.D. Anderson Cancer Center enasidenib NCT03383575

A Phase 1/2 Study of Bleximenib in Participants With Acute Leukemia (cAMeLot-1)

NPM1 mutation Johnson & Johnson bleximenib NCT04811560

Adjuvant Therapy of Ensartinib in Stage IB-IIIA ALK-positive Non-small Cell Lung Cancer

ALK fusion Hebei Medical University Fourth Hospital ensartinib NCT05241028

Therapeutic Cancer Vaccine (AST-301, pNGVL3-hICD) in Gastric Cancer

HER2-low / ultralow (IHC 1+ or 2+/ISH-) Aston Sci AST-301 NCT05771584

Dual-Targeting CAR-NK Cells Targeting Mesothelin (MSLN) and MUC1 in Advanced Pancreatic Ductal Adenocarcinoma

Claudin 18.2 expression Beijing Biotech EB-DNK101 dual-targeting CAR-NK cells (MSLN + MUC1), EB-DNK102 dual-targeting CAR-NK cells (CLDN18.2 + MUC1) NCT07480928

Radiation and TSR-042 (Dostarlimab) in People With Endometrial Cancer After They Receive Surgery

MSI-H / dMMR Memorial Sloan Kettering Cancer Center dostarlimab NCT04774419

JMT101 in Combination With Osimertinib, Versus Cisplatin-pemetrexed in Participants With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Characterized by Epithermal Growth Factor Receptor (EGFR) Exon 20ins Mutations

EGFR exon 20 insertion Shanghai JMT-Bio JMT101, osimertinib NCT06380348

Adjuvant Encorafenib and Binimetinib in High-risk Stage II Melanoma With a BRAF Mutation.

BRAF V600E Pierre Fabre Medicament encorafenib, binimetinib NCT05270044

Nivolumab and Ipilimumab With or Without Local Consolidation Therapy in Treating Patients With Stage IV Non-Small Cell Lung Cancer

ROS1 fusionRET fusion or mutation M.D. Anderson Cancer Center ipilimumab, nivolumab NCT03391869

Clinical Trial for Safety and Effectiveness Evaluation of Tarlatamab (AMG757) With Etoposide, Carboplatin and Atezolizumab in Transformed Small Cell Lung Cancer Patients From Adenocarcinoma After EGFR TKI Treatment

EGFR exon 19 deletion / L858R Sehhoon Park atezolizumab NCT06830694

Trilaciclib in Patients Receiving Sacituzumab Tirumotecan for EGFR-mutated, Advanced Non-Small Cell Lung Cancer (NSCLC)

EGFR exon 19 deletion / L858R The First Affiliated Hospital of Xiamen University sacituzumab tirumotecan NCT06992739

Fulzerasib Sequential Sintilimab Plus Platinum-Doublet Neoadjuvant Therapy for Resectable KRAS G12C-Mutant NSCLC

KRAS G12C Jianxing He fulzerasib, sintilimab NCT07492342

Phase 1/2a Study of JAB-21822 Plus JAB-3312 in Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation

KRAS G12C Allist Pharmaceuticals glecirasib, sitneprotafib NCT05288205

Testing Two Different Treatment Schedules of Dabrafenib and Trametinib for Skin Cancer Which Has Spread

BRAF V600E National Cancer Institute (NCI) dabrafenib, trametinib NCT02196181

Niraparib Maintenance in HRD-Positive Advanced Ovarian Cancer Following Front-Line Chemotherapy + Bevacizumab

BRCA1/2 mutation Peking University Cancer Hospital & Institute niraparib NCT06141265

Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial

BRCA1/2 mutation Massachusetts General Hospital talazoparib NCT03990896

Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)

IDH1/2 mutation National Cancer Institute (NCI) enasidenib, venetoclax NCT06672146

Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A MyeloMATCH Treatment Trial)

IDH1/2 mutation National Cancer Institute (NCI) enasidenib NCT06577441

AG-120 in People With IDH1 Mutant Chondrosarcoma

IDH1/2 mutation Memorial Sloan Kettering Cancer Center ivosidenib NCT04278781

A Phase 2 Clinical Study of Ziftomenib in Patients With Relapsed or Refractory NPM1-Mutated Acute Myeloid Leukemia

NPM1 mutation Kyowa Kirin ziftomenib NCT07623616

A Study of an FGFR2/3 Inhibitor (CGT4859) in Patients With Cholangiocarcinoma and Other Advanced Solid Tumors

FGFR3 alteration (mutation or fusion)FGFR2 fusion or rearrangement Cogent Biosciences CGT4859 NCT06777316

Neoadjuvant WX-0593 in Resectable ALK-positive or ROS1-positive Non-small Cell Lung Cancer

ALK fusionROS1 fusion Pingping Song iruplinalkib NCT05765877

Repotrectinib in ROS1-positive Non-small Cell Lung Cancer Patients With Active Brain Metastasis

ROS1 fusion MedSIR repotrectinib NCT06315010

A Study of EP0031 (Lunbotinib) in Patients With Advanced RET-altered Malignancies

RET fusion or mutation Ellipses Pharma lunbotinib, Platinum chemotherapy NCT05443126

Clinical Study of SHR-A1811 With or Without Letrozole in Neoadjuvant Therapy for Early-Stage HR-Positive, HER2-Low Breast Cancer

HER2-low / ultralow (IHC 1+ or 2+/ISH-) First Hospital of China Medical University trastuzumab rezetecan, letrozole, TAC/AC-T NCT07305246

HER2-PET Imaging in HER2-low Breast Cancers

HER2-low / ultralow (IHC 1+ or 2+/ISH-) Centre de recherche du Centre hospitalier universitaire de Sherbrooke NCT06732336

Dual-Target CLDN18.2/HER2 CAR-NK Cells for Advanced Esophageal Adenocarcinoma

Claudin 18.2 expression Beijing Biotech EBNK-1822H2 dual-target CLDN18.2/HER2 CAR-NK cells NCT07622940

Dual-target CLDN18.2/HER2 CAR-NK Cells for Advanced Gastric/GEJ Cancer

Claudin 18.2 expression Beijing Biotech EB-DT-CAR-NK NCT07551362

Study for AZD4360 in Participants With Advanced Solid Tumours

Claudin 18.2 expression AstraZeneca AZD4360 NCT06921928

Clinical Trial of TB511 in Advanced Solid Tumors

MSI-H / dMMR Twinpig Biolab TB511, pembrolizumab NCT06400160

Pembrolizumab Plus Lenvatinib in Combination With Belzutifan in Solid Tumors (MK-6482-016)

MSI-H / dMMR MSD (Merck & Co.) pembrolizumab, Belzutifan, lenvatinib NCT04976634

A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor

MSI-H / dMMR Eisai E7386, lenvatinib NCT04008797

Olutasidenib DDI Study in Patients With IDH1 Mutation Positive Malignancies

IDH1/2 mutation Rigel Pharmaceuticals olutasidenib, CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP3A4, and OATP1B1 Probe Substrates NCT07486713

FCN-159 Monotherapy Versus Chemotherapy by Investigator's Choice in Pediatric Low-grade Glioma Patients With BRAF Alteration

BRAF V600E Fosun Pharma luvometinib NCT07004075

A Study of Ivosidenib or Enasidenib in Combination With Induction Therapy and Consolidation Therapy, Followed by Maintenance Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myedysplastic Syndrome EB2, With an IDH1 or IDH2 Mutation, Respectively, Eligible for Intensive Chemotherapy

IDH1/2 mutation Stichting Hemato-Oncologie voor Volwassenen Nederland ivosidenib, enasidenib NCT03839771

Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation

ESR1 mutation LeonaBio lasofoxifene, abemaciclib, fulvestrant NCT05696626

A Study to Compare the Efficacy, Safety, Immunogenicity, and Pharmacokinetic Profile of HLX17 Vs. Keytruda® in the First-Line Treatment of Advanced Non-squamous Non-small Cell Lung Cancer

ROS1 fusion Henlius HLX17, pembrolizumab NCT06847334

Phase Ib/II Study of Vebreltinib With Furmonertinib in NSCLC Patients With c-Met Amplification After EGFR-TKI Failure

EGFR exon 19 deletion / L858R Peking University Cancer Hospital & Institute vebreltinib, furmonertinib NCT07087223

Osimertinib, Surgery, and Radiation Therapy in Treating Patients With Stage IIIB or IV Non-small Cell Lung Cancer With EGFR Mutations, NORTHSTAR Study

EGFR exon 19 deletion / L858R M.D. Anderson Cancer Center osimertinib NCT03410043

A Multicenter, Single-arm Phase II Study to Evaluate the Efficacy and Safety of Fulzerasib (IBI351) in Combination With Ivonescimab (AK-112) in First-line Treatment of Advanced or Metastatic Non-small Cell Lung Cancer Patients With KRAS G12C Mutation

KRAS G12C Shanghai Chest Hospital fulzerasib, ivonescimab NCT06936644

A Study of D3S-001 Monotherapy or Combination Therapy in Subjects With Advanced Solid Tumors With a KRAS p.G12C Mutation

KRAS G12C D3 Bio D3S-001, pembrolizumab, cetuximab NCT05410145

Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)

KRAS G12C Eli Lilly olomorasib, pembrolizumab, cetuximab NCT04956640

Efficacy And Safety Of Hydroxychloroquine Combined With Methotrexate, Capecitabine And Bevacizumab Vs. Regorafenib In Participants With Refractory Metastatic Colorectal Cancer With Mutations In RAS Genes

KRAS G12CKRAS G12D Sergey Orlov, MD experimental group x-MAP, regorafenib NCT06949982

GFH375 Monotherapy and Combination Therapy as First-Line Treatment for Advanced KRAS G12D-Mutant Non-Small Cell Lung Cancer

KRAS G12D Genfleet Therapeutics VS-7375, cetuximab NCT07554859

iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation

KRAS G12D M.D. Anderson Cancer Center Mesenchymal Stromal Cells-derived Exosomes with KRAS G12D siRNA NCT03608631

Dabrafenib and Trametinib Before and After Surgery in Treating Patients With Stage IIIB-C Melanoma With BRAF V600 Mutation

BRAF V600E M.D. Anderson Cancer Center dabrafenib, trametinib NCT02231775

Rash & Diarrhea Prophylaxis With Capivasertib

PIK3CA activating mutation Maryam Lustberg capivasertib, Loperamide, fulvestrant, Ceterizine NCT07426822

SNV4818 in Participants With Advanced Solid Tumors

PIK3CA activating mutation Pikavation Therapeutics SNV4818, fulvestrant, palbociclib NCT06736704

I/II Phase Study Evaluating M1774 in Combination With Fulvestrant in HR+ and HER2- Advanced Breast Cancers

BRCA1/2 mutation Institut Paoli-Calmettes M1774, fulvestrant NCT05986071

Fluzoparib Combined With Camrelizumab for Neoadjuvant Treatment of Embryogenic BRCA Mutation HER2 Negative Breast Cancer: an Open, Single Arm, Multicenter Study

BRCA1/2 mutation Peking University People's Hospital camrelizumab, fluzoparib NCT05576389

IDH1 (AG 120) Inhibitor in Patients With IDH1 Mutated Myelodysplastic Syndrome

IDH1/2 mutation Groupe Francophone des Myelodysplasies ivosidenib NCT03503409

Maximum Tolerated Dose, Safety, and Efficacy of Rhenium Nanoliposomes in Recurrent Glioma (ReSPECT)

IDH1/2 mutation Cerenome Rhenium Liposome Treatment NCT01906385

Combination of Midostaurin and Gemtuzumab Ozogamicin in First-line Standard Therapy for Acute Myeloid Leukemia (MOSAIC)

FLT3 mutation (ITD/TKD) Technische Universität Dresden midostaurin, gemtuzumab ozogamicin NCT04385290

Patritumab Deruxtecan in Patients With Solid Tumor Harboring an NRG1 Fusion

NRG1 fusion Samsung Medical Center patritumab deruxtecan NCT06383884

Phase II Study of Trastuzumab Rezetecan Combined With Adebrelimab and Lenvatinib as First-Line Therapy for Advanced HER2-Positive/HER2-Low Biliary Tract Cancer

HER2-low / ultralow (IHC 1+ or 2+/ISH-) Peking Union Medical College Hospital trastuzumab rezetecan, adebrelimab, lenvatinib NCT07670273

Phase II Study of Trastuzumab Rezetecan Combined With Adebrelimab and Lenvatinib in Advanced HER2-Positive/Low-Expression Biliary Tract Cancer

HER2-low / ultralow (IHC 1+ or 2+/ISH-) Peking Union Medical College Hospital trastuzumab rezetecan, adebrelimab, lenvatinib NCT07704177

Dual-Target CAR-NK Cells Targeting Mesothelin (MSLN) and MUC1 in Advanced Pancreatic Ductal Adenocarcinoma

Claudin 18.2 expression Beijing Biotech EB-DNK101 dual-targeting CAR-NK cells (MSLN + MUC1), EB-DNK102 dual-targeting CAR-NK cells (CLDN18.2 + MUC1) NCT07627711

The Phoenix Trial: Phase II Trial of Cemiplimab for the Non-operative Management of Localized dMMR Colon Cancer

MSI-H / dMMR M.D. Anderson Cancer Center cemiplimab NCT05961709

FOG-001 in Locally Advanced or Metastatic Solid Tumors

MSI-H / dMMR Parabilis Medicines FOG-001, nivolumab, bevacizumab NCT05919264

Atezolizumab in Patients With MSI-h/MMR-D Stage II High Risk and Stage III Colorectal Cancer Ineligible for Oxaliplatin

MSI-H / dMMR AIO-Studien-gGmbH atezolizumab, IMM-101 NCT05118724

Two Combination Treatment Regimens of Nivolumab and Ipilimumab in Patients With dMMR and / or MSI mCRC.

MSI-H / dMMR GERCOR - Multidisciplinary Oncology Cooperative Group nivolumab, ipilimumab NCT04730544

Neoadjuvant Toripalimab With or Without Celecoxib in dMMR/MSI-H Colorectal Cancer

MSI-H / dMMR Sun Yat-sen University toripalimab NCT03926338

Firmonertinib Combined With Intrathecal Injection for the Treatment of EGFR Mutant NSCLC With Leptomeningeal Metastases

EGFR exon 19 deletion / L858R Union Hospital, Tongji Medical College, Huazhong University of Science and Technology furmonertinib NCT07092202

A Study of SKB264 in Combination With Osimertinib Versus Osimertinib in Patients With Epidermal Growth Factor Receptor (EGFR) Mutations, Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer

EGFR exon 19 deletion / L858R Kelun-Biotech sacituzumab tirumotecan, osimertinib NCT06670196

Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004)

EGFR exon 19 deletion / L858R MSD (Merck & Co.) sacituzumab tirumotecan NCT06074588

REZILIENT3 (REsearching ZIpaLertinib In Egfr Non-small Cell Lung Cancer Tumors)

EGFR exon 19 deletion / L858REGFR exon 20 insertion Taiho Pharmaceutical zipalertinib NCT05973773

A Study of BL-M07D1 Versus Investigator's Choice of Chemotherapy in Patients With HER2-low Recurrent/Metastatic Breast Cancer

HER2-low / ultralow (IHC 1+ or 2+/ISH-) Baili-Bio / SystImmune BL-M07D1 NCT06957886

A Phase III Randomized Study in CLDN18.2-positive Unresectable Locally Advanced Gastric Cancer Patients

Claudin 18.2 expression Suzhou Immunofoco Biotechnology CAR T cells, Control NCT07103668

COLLISION RELAPSE Trial

MSI-H / dMMR Amsterdam UMC, location VUmc NCT05861505

Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma (MK-3475-C93/KEYNOTE-C93/GOG-3064/ENGOT-en15)

MSI-H / dMMR MSD (Merck & Co.) pembrolizumab NCT05173987

Zorifertinib Plus Intra-Ommaya CSF Chemotherapy for Leptomeningeal Progression in NSCLC After Third-Generation EGFR-TKI

EGFR exon 19 deletion / L858R Cancer Institute and Hospital, Chinese Academy of Medical Sciences Zorifertinib Plus Intra-Ommaya CSF Chemotherapy NCT07551414

AMT-116 in Combination With AK112 in Patients With Lung Cancer

EGFR exon 19 deletion / L858R Multitude Therapeutics AMT-116, ivonescimab NCT07590531

Whole Body HER3 Quantification With Radiolabelled Patritumab Deruxtecan (HER3-DXd) PET/CT

EGFR exon 19 deletion / L858R The Netherlands Cancer Institute patritumab deruxtecan NCT06222489

Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib

EGFR exon 19 deletion / L858R Johnson & Johnson amivantamab, lazertinib, Doxycycline, Minocycline NCT06120140

Osimertinib Alone or With Chemotherapy for EGFR-Mutant Lung Cancers

EGFR exon 19 deletion / L858R Memorial Sloan Kettering Cancer Center osimertinib NCT04410796

The Efficacy and Safety of IBI351, Cetuximab β Combined With FOLFIRI as First-line /IBI351, Cetuximab β as Second-line in the Treatment of KRAS G12C-mutated Metastatic Colorectal Cancer

KRAS G12C Second Affiliated Hospital, Zhejiang University, School of Medicine fulzerasib, cetuximab NCT06959589

Pre-operative Targeted Treatments in Molecularly Selected Resectable Colorectal Cancer (UNICORN)

KRAS G12CMSI-H / dMMR Gruppo Oncologico del Nord-Ovest trastuzumab deruxtecan, durvalumab, panitumumab, botensilimab NCT05845450

The TG01 Study With TG01/QS-21 Vaccine in Patients With High-risk Smouldering Multiple Myeloma and Multiple Myeloma

KRAS G12CKRAS G12D Oslo University Hospital TG01 NCT05841550

Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS

KRAS G12CKRAS G12D Revolution Medicines daraxonrasib NCT05379985

HRS-4642 in Combination With Nimotuzumab and Chemotherapy for BRPC With KRAS G12D Mutation

KRAS G12D Zhejiang University HRS-4642 NCT07240766

Ulixertinib in People With Histiocytic Neoplasms

BRAF V600E Memorial Sloan Kettering Cancer Center ulixertinib NCT06411821

Combination Therapy for BRAF-V600E Metastatic CRCm

BRAF V600E Vall d'Hebron Institute of Oncology encorafenib, cetuximab, bevacizumab NCT06411600

A Study to Evaluate Tovorafenib in Pediatric and Young Adult Participants With Relapsed or Progressive Low-Grade Glioma and Advance Solid Tumors

BRAF V600E Day One Biopharmaceuticals tovorafenib NCT04775485

Talazoparib in Advanced Breast Cancer Patients With Homologous Recombinant Deficiency

BRCA1/2 mutation Seoul National University Hospital talazoparib NCT04892693

Ivosidenib as Maintenance Therapy in Transplant-Ineligible IDH1-mutated AML and HR-MDS

IDH1/2 mutation Ruijin Hospital ivosidenib NCT07607418

Safety and Efficacy of Quizartinib in Children and Young Adults With Acute Myeloid Leukemia (AML), a Cancer of the Blood

FLT3 mutation (ITD/TKD) Daiichi Sankyo quizartinib, Intrathecal (IT) triple chemotherapy prophylaxis NCT03793478

Alpha/Beta T Cell and CD19+ B Cell Depletion in Allogeneic Stem Cell Transplantation in Patients With Malignant Diseases

FLT3 mutation (ITD/TKD) University of Florida NCT05800210

Genomic and Transcriptomic Predictors of Sequential SG Sensitivity After T-DXd in ER+/HER2-Low Metastatic Breast Cancer

HER2-low / ultralow (IHC 1+ or 2+/ISH-) British Columbia Cancer Agency sacituzumab govitecan NCT06665178

Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03)

HER2-low / ultralow (IHC 1+ or 2+/ISH-) AstraZeneca durvalumab, trastuzumab, trastuzumab deruxtecan, pembrolizumab NCT04379596

Phase Ⅱ Clinical Trial of Cadonilimab Combined With Anti-angiogenic Agents in Metastatic dMMR/MSI-H CRC

MSI-H / dMMR Fudan University cadonilimab, bevacizumab, regorafenib, fruquintinib NCT07003022

Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program

MSI-H / dMMR Mayo Clinic nivolumab NCT06265285

Study of Atezolizumab + FLOT vs. FLOT Alone in Patients With GC/GEJ and High Immune Responsiveness

MSI-H / dMMR Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest atezolizumab NCT03421288

Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158)

MSI-H / dMMR MSD (Merck & Co.) pembrolizumab NCT02628067

Roll-over Study to Allow Access to Certinib (LDK378) for Patients Who Are on Ceritinib Treatment in a Novartis-sponsored Study

ALK fusion Novartis ceritinib NCT02584933

SIS-Reinforced vs. Conventional Anastomosis for Mid-to-Low Rectal Cancer: A Multicenter RCT on Anastomotic Leak

MSI-H / dMMR Beijing Chao Yang Hospital NCT07209787

A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)

KRAS G12C Amgen sotorasib, pembrolizumab NCT05920356

A Multicenter Study of IBI343 Monotherapy Versus Placebo in Subjects With Previously Treated, Claudin (CLDN) 18.2-positive, Pancreatic Cancer(G-HOPE-002)

Claudin 18.2 expression Innovent Biologics IBI343 NCT07066098

Testing the Addition of Atezolizumab to Combination Chemotherapy or Atezolizumab Alone for Metastatic Colon or Rectal Cancer, the COMMIT Study

MSI-H / dMMR National Cancer Institute (NCI) atezolizumab, bevacizumab NCT02997228

Sacituzumab Tirumotecan Plus Third-Generation TKI With/Without Radiotherapy for EGFR-Mutant NSCLC Brain Metastases

EGFR exon 19 deletion / L858R Zhejiang Cancer Hospital sacituzumab tirumotecan NCT07343479

Study of IBI3005 Combination Therapy in Participants With Unresectable, Locally Advanced or Metastatic Solid Tumors

EGFR exon 19 deletion / L858R Innovent Biologics IBI3005, sintilimab, bevacizumab, limertinib NCT07612137

A Phase 2 Study of Osimertinib in Combination With Selumetinib in EGFR Inhibitor naïve Advanced EGFR Mutant Lung Cancer

EGFR exon 19 deletion / L858R Dana-Farber Cancer Institute osimertinib, selumetinib NCT03392246

Boosting Osimertinib Blood Brain Barrier Penetration

EGFR exon 19 deletion / L858R Maastricht University Medical Center osimertinib NCT07485452

DZD6008 Combination Therapy in Patients With Locally Advanced or Metastatic NSCLC With EGFR Mutation (TIAN-SHAN7)

EGFR exon 19 deletion / L858R Dizal Pharmaceuticals DZD6008 NCT07070440

Study of BEBT-109 in Subjects With Non-Small Cell Lung Cancer Carrying EGFR Exon 20 Insertion Mutations

EGFR exon 19 deletion / L858REGFR exon 20 insertionHER2 (ERBB2) activating mutation BeBetter Med BEBT-109 Capsules NCT06514027

Phase II Clinical Study of Befotertinib in EGFR Non-classical Mutant NSCLC

EGFR exon 19 deletion / L858REGFR exon 20 insertion Second Affiliated Hospital, Zhejiang University, School of Medicine befotertinib NCT06863506

A Study to Assess the Efficacy and Safety of WSD0922-FU in Patients With EGFRm+ Advanced Non-small Cell Lung Cancer

EGFR exon 19 deletion / L858R Wayshine Biopharm WSD0922 NCT06631989

Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)

EGFR exon 19 deletion / L858R SWOG Cancer Research Network capmatinib, osimertinib, ramucirumab NCT05642572

Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change

EGFR exon 19 deletion / L858REGFR exon 20 insertion National Cancer Institute (NCI) osimertinib NCT03191149

Sotorasib in Combination With Trastuzumab Deruxtecan for the Treatment of Locally Advanced and Metastatic Non-small Cell Lung Cancer With a KRAS G12C Mutation

KRAS G12C National Cancer Institute (NCI) sotorasib, trastuzumab deruxtecan NCT07012031

Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC

KRAS G12CKRAS G12D Revolution Medicines elironrasib, daraxonrasib, pembrolizumab, zoldonrasib NCT06162221

Isunakinra Alone and in Combination With Pembrolizumab in Patients With Colorectal Cancer (MSS)

KRAS G12CKRAS G12D Buzzard Pharmaceuticals isunakinra NCT06634875

Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients

KRAS G12CKRAS G12D Tango Therapeutics TNG462, zoldonrasib, daraxonrasib NCT06922591

A Phase 1/2a Study of IMM-1-104 in Participants With Advanced or Metastatic Solid Tumors

KRAS G12CKRAS G12DBRAF V600E Immuneering atebimetinib, dabrafenib, pembrolizumab NCT05585320

Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients

KRAS G12CKRAS G12D National Cancer Institute (NCI) Anti-KRAS G12V mTCR PBL, aldesleukin NCT03190941

A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Non-Small Cell Lung Cancer

KRAS G12D Verastem VS-7375 NCT07659782

A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Colorectal Cancer

KRAS G12D Verastem VS-7375, cetuximab, panitumumab NCT07659795

A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic Cancer

KRAS G12D Verastem VS-7375, cetuximab, panitumumab NCT07644559

Safety and Efficacy of IB-FOLFIRI in BRAF V600E-Mutant Metastatic Colorectal Cancer

BRAF V600E Sun Yat-sen University iparomlimab and tuvonralimab, bevacizumab NCT07150247

Study of Cemiplimab Combined With Dabrafenib and Trametinib in People With Anaplastic Thyroid Cancer

BRAF V600E Memorial Sloan Kettering Cancer Center dabrafenib, trametinib NCT04238624

PLUG-IN: Pembrolizumab Combined With Enfortumab Vedotin for Advanced Melanoma Patients

BRAF V600E Grupo Español Multidisciplinar de Melanoma enfortumab vedotin, pembrolizumab NCT06906822

A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases

BRAF V600E SWOG Cancer Research Network binimetinib, encorafenib, ipilimumab, nivolumab NCT04511013

Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors

PIK3CA activating mutation Ensem Therapeutics ETX-636 dose escalation, fulvestrant NCT06993844

Neoadjuvant Envafolimab Plus Disitamab Vedotin and Carboplatin in Resectable HER2-Mutant Non-Small-Cell Lung Cancer

HER2 (ERBB2) activating mutation Guangdong Provincial People's Hospital disitamab vedotin NCT06734182

A Safety And Efficacy Study Of Allogeneic CAR Gamma-Delta T Cells in Subjects With Relapsed/Refractory Solid Tumors

BRCA1/2 mutation Ever Supreme Bio Technology HLA-G-CAR.BiTE allogeneic γδ T cells NCT06150885

Olutasidenib Combined With Co-targeted Therapy in Relapsed or Refractory IDH1-mutated Myeloid Malignancies Harboring Activated Signaling Pathway Mutations

IDH1/2 mutationFLT3 mutation (ITD/TKD) M.D. Anderson Cancer Center olutasidenib, venetoclax, gilteritinib, Ruxolitinib NCT07032727

All-Trans Retinoic Acid (ATRA) Plus PD-1 Inhibition in Recurrent IDH-Mutant Glioma

IDH1/2 mutation Stephen Bagley, MD, MSCE retifanlimab, All-trans retinoic acid NCT05345002

A Study Testing the Effect of Immunotherapy (Ipilimumab and Nivolumab) in Patients With Recurrent Glioma With Elevated Mutational Burden

IDH1/2 mutation National Cancer Institute (NCI) ipilimumab, nivolumab NCT04145115

A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)

FLT3 mutation (ITD/TKD)NPM1 mutation Sumitomo Pharma America enzomenib, azoles, venetoclax, gilteritinib NCT04988555

A Randomized Phase II Study of Hyperbaric Oxygen in Improving Engraftment in Umbilical Cord Blood Stem Cell Transplant

NPM1 mutation University of Rochester Hyperbaric oxygen NCT03739502

Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders

NPM1 mutation Masonic Cancer Center, University of Minnesota HSCT with TBI Regimen, HSCT with Non-TBI Regimen NCT03314974

Efficacy of Pemigatinib in Patients With Solid Tumors Characterized by an Alteration of the Gene FGFR in Tumor Cells

FGFR3 alteration (mutation or fusion) UNICANCER pemigatinib NCT06653777

Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)

ALK fusion Roche entrectinib NCT02568267

Study Of Entrectinib (Rxdx-101) in Children and Adolescents With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment Options

ROS1 fusionNTRK1/2/3 fusion Roche entrectinib NCT02650401

Sequencing SG vs. T-DXd in HER2-Low/TROP2-High Metastatic Breast Cancer

HER2-low / ultralow (IHC 1+ or 2+/ISH-) Fudan University sacituzumab govitecan, trastuzumab deruxtecan NCT07368543

A Phase II Study of HLX22 in Combination With Trastuzumab Deruxtecan in HER2-low, Hormone Receptor Positive Locally Advanced or Metastatic Breast Cancer Patients

HER2-low / ultralow (IHC 1+ or 2+/ISH-) Henlius HLX22, trastuzumab deruxtecan NCT06832202

A Phase II Study of SHR-A1811 Combined With Radiotherapy in HER2-positive and HER2-low Breast Cancer Brain Metastases

HER2-low / ultralow (IHC 1+ or 2+/ISH-) Union Hospital, Tongji Medical College, Huazhong University of Science and Technology trastuzumab rezetecan NCT06975462

IBI343 Combined With Chemotherapy in Advanced Pancreatic Cancer

Claudin 18.2 expression Zhejiang Cancer Hospital IBI343 NCT07692750

A Trial to Evaluate Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of TST001 in Advanced or Metastatic Solid Tumors

Claudin 18.2 expression Transcenta Therapeutics osemitamab, nivolumab NCT04495296

A Study of Zolbetuximab (IMAB362) in Adults With Gastric Cancer

Claudin 18.2 expression Astellas zolbetuximab, pembrolizumab, nivolumab NCT03505320

Sintilimab Combined With LDRT for Neoadjuvant Treatment of Locally Advanced dMMR/MSI-H Gastric Cancer

MSI-H / dMMR West China Hospital sintiliman plus LDRT NCT06426654

Study of DECOY20 With or Without Tislelizumab in Patients With Advanced Solid Tumors

MSI-H / dMMR Indaptus Therapeutics Decoy20, tislelizumab NCT05651022

Testing Nivolumab and Ipilimumab With Short-Course Radiation in Locally Advanced Rectal Cancer

MSI-H / dMMR National Cancer Institute (NCI) ipilimumab, nivolumab NCT04751370

Explore the Mechanisms Underlying Disease Resistance and Potential Primary Resistance Mechanism of Induction Therapy Lorlatinib in Resectable Non-small Cell Lung Cancer (NSCLC) Harboring ALK Positive Mutation Revealed by Single-cell RNA Sequencing and Spatial Transcriptomics

ALK fusion The First Affiliated Hospital of Guangzhou Medical University lorlatinib NCT06893354

Pralsetinib DDI Study in Patients With Advanced or Metastatic Solid Tumors

RET fusion or mutation Rigel Pharmaceuticals pralsetinib, CYP3A4, CYP2C8, and CYP2C9 substrates, and hormonal contraceptive NCT07704658

A Study of XY0206 Versus Salvage Chemotherapy In Patients With Relapsed or Refractory AML With FLT3-ITD-Mutation (ALIVE)

FLT3 mutation (ITD/TKD) Shijiazhuang Yiling Pharmaceutical XY0206, Salvage Chemotherapy NCT05876832

Sacituzumab Tirumotecan（Sac-TMT） and Brain Radotherapy for EGFR+ NSCLC With Brain Mets

EGFR exon 19 deletion / L858R Xiaorong Dong sacituzumab tirumotecan NCT07789444

A Phase 1/2 Clinical Trial to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMBD-501 in Patients With HER3-Expressing Solid Tumors

EGFR exon 19 deletion / L858R Hummingbird Bioscience ENV-501 NCT06956690

A Phase Ⅰ/Ⅱa Clinical Study of GEN-725 in Combination With Dositinib

EGFR exon 19 deletion / L858R Henan Genuine Biotech GEN-725 tablets + Dositinib mesylate tablets NCT07362940

Phase Ib/II Study of Almonertinib Combined With SHR-1701 in the Treatment of Relapsed or Advanced Non-small Cell Lung Cancer

EGFR exon 19 deletion / L858R Jiangsu Hengrui aumolertinib NCT05503888

Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)

EGFR exon 19 deletion / L858RBRCA1/2 mutation Genmab rinatabart sesutecan, bevacizumab, pembrolizumab NCT05579366

A Study of GFH375 Combined With Cetuximab or Chemotherapy in Participants With Solid Tumors Harboring KRAS G12D Mutation

KRAS G12D Genfleet Therapeutics VS-7375, cetuximab NCT07259590

Atezolizumab With Chemotherapy in Treating Patients With Anaplastic or Poorly Differentiated Thyroid Cancer

BRAF V600E M.D. Anderson Cancer Center atezolizumab, bevacizumab, cobimetinib, vemurafenib NCT03181100

A Study to Test Inavolisib Treatments in Participants With Early-Stage, PIK3CA-Mutated Breast Cancer

PIK3CA activating mutation Roche inavolisib, ribociclib, letrozole, giredestrant NCT07054190

Clinical Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SYS6045 in Patients With HER2-Positive, Expressing, or Mutated Advanced Malignant Solid Tumors

HER2 (ERBB2) activating mutation CSPC SYS6045 NCT07122063

Carboplatin Chemotherapy Before Surgery for People With High-Risk Prostate Cancer and an Inherited BRCA1 or BRCA2 Gene Mutation

BRCA1/2 mutation SWOG Cancer Research Network NCT05806515

Abemaciclib (LY2835219) in Patients With Recurrent Primary Brain Tumors

IDH1/2 mutation Memorial Sloan Kettering Cancer Center abemaciclib NCT03220646

Peptide Vaccine To Prevent Acquired Resistance In Patients With Advanced ALK+ NSCLC

ALK fusion Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Peptide vaccine NCT05950139

Cabozantinib in Patients With RET Fusion-Positive Advanced Non-Small Cell Lung Cancer and Those With Other Genotypes: ROS1 or NTRK Fusions or Increased MET or AXL Activity

ROS1 fusionRET fusion or mutationNTRK1/2/3 fusion Memorial Sloan Kettering Cancer Center cabozantinib NCT01639508

A Phase 2 Study to Evaluate the Efficacy, Safety and Pharmacokinetics of YL202 in Patients With BC

HER2-low / ultralow (IHC 1+ or 2+/ISH-) MediLink Therapeutics YL202 NCT06439771

IBI343 Combined With Sintilimab Plus Chemotherapy in Gastric Cancer

Claudin 18.2 expression Ruijin Hospital IBI343, sintilimab, S-1 NCT07025889

Pembrolizumab With Olaparib as Combined Therapy in Metastatic Pancreatic Cancer

MSI-H / dMMR Cambridge University Hospitals NHS Foundation Trust pembrolizumab, olaparib NCT05093231

Immunotherapy in Patients With Early dMMR Rectal Cancer

MSI-H / dMMR Odense University Hospital nivolumab, ipilimumab NCT05732389

A Global Study to Assess the Effects of Osimertinib in Participants With EGFRm Stage IA2-IA3 NSCLC Following Complete Tumour Resection

EGFR exon 19 deletion / L858R AstraZeneca osimertinib NCT05120349

SRS for NSCLC With Oligo-residual Intracranial Disease After First-line 3rd Generation EGFR-TKI

EGFR exon 19 deletion / L858R Fudan University EGFR-TK Inhibitor NCT06020066

A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer

EGFR exon 19 deletion / L858REGFR exon 20 insertion Johnson & Johnson amivantamab, lazertinib, Direct Oral Anticoagulant (DOAC), Low Molecular Weight Heparin (LMWH) NCT05498428

Phase II Study of Sacituzumab Tirumotecan in Combination With Osimertinib for Neoadjuvant Treatment in Patients With Resectable Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer

EGFR exon 19 deletion / L858R Kelun-Biotech sacituzumab tirumotecan, osimertinib NCT07329322

A Study of Sotorasib in People With Non-Small Cell Lung Cancer

KRAS G12C Memorial Sloan Kettering Cancer Center sotorasib NCT06582771

A Study of JAB-21822 in Advanced or Metastatic NSCLC With KRAS p.G12C and STK11 Co-mutation and Wild-type KEAP1

KRAS G12C Allist Pharmaceuticals glecirasib NCT05276726

FOLFIRI and Bevacizumab With or Without Pelareorep for Second-Line Treatment of Metastatic RAS-Mutated, Microsatellite-Stable Colorectal Cancer

KRAS G12CKRAS G12D Oncolytics Biotech bevacizumab, Pelareorep NCT07446322

A Study of Avutometinib and Defactinib in People With Thyroid Cancer

KRAS G12CKRAS G12DALK fusionRET fusion or mutationNTRK1/2/3 fusion Memorial Sloan Kettering Cancer Center avutometinib, defactinib NCT06007924

Beamion 44: A Study to Test How Well Zongertinib is Tolerated by People With Advanced Non-small Cell Lung Cancer With HER2 Mutations When Given in Combination With Chemotherapy With or Without Pembrolizumab

HER2 (ERBB2) activating mutation Boehringer Ingelheim zongertinib, pembrolizumab NCT07486817

A Phase II Clinical Study to Evaluate the Safety, Efficacy, Pharmacokinetics/Pharmacodynamics of JSKN033 in Patients With Advanced Non-Small Cell Lung Cancer

HER2 (ERBB2) activating mutation Jiangsu Alphamab Biopharmaceuticals JSKN033 Injection NCT07283198

Carboplatin or Olaparib for BRcA Deficient Prostate Cancer

BRCA1/2 mutation VA Office of Research and Development olaparib NCT04038502

A Phase 2 Study Evaluating Olutasidenib in Patients With IDH1-mutated Clonal Cytopenia of Undetermined Significance and Lower-risk Myelodysplastic/Syndromes/Chronic Myelomonocytic Leukemia.

IDH1/2 mutation M.D. Anderson Cancer Center olutasidenib NCT06566742

A Study of Oral Erdafitinib in People With Recurrent Non-Invasive Bladder Cancer

FGFR3 alteration (mutation or fusion) Memorial Sloan Kettering Cancer Center erdafitinib NCT04917809

A Study of HS-10365 in Patients With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer

RET fusion or mutation Hansoh Pharma HS-10365 capsules NCT06147570

ANO31905 in Combination With Chemotherapy for CLDN18.2-Positive Locally Advanced Unresectable or Metastatic Pancreatic Cancer

Claudin 18.2 expression Anova Innovation ANO31905 NCT07444541

TAC T-cells for the Treatment of Claudin 18.2 Positive Solid Tumors (TACTIC-3)

Claudin 18.2 expression Triumvira Immunologics TAC01-CLDN18.2 NCT05862324

Neoadjuvant SHR-A1811 and SHR-A1701 ± Pertuzumab for Potentially Immunotherapy-Sensitive GC or GEJ Adenocarcinoma

MSI-H / dMMR The First Affiliated Hospital with Nanjing Medical University trastuzumab, pertuzumab NCT07716111

The Efficacy and Safety of Neoadjuvant Therapy With Iparomlimab and Tuvonralimab in Locally Advanced MSI-H/dMMR Colorectal Cancer: An Prospective, Single-Arm Study (Neo-IT)

MSI-H / dMMR Sir Run Run Shaw Hospital Ipalolimab and Tovorilimab NCT07160647

A Study to Evaluate the Safety and the Activity of S095029 as Part of Combination Therapy in Advanced Gastroesophageal Junction/Gastric Cancers.

MSI-H / dMMR Servier Bio-Innovation S095029, pembrolizumab NCT06116136

Elacestrant + Everolimus in Patients ER+/HER2-, ESR1mut, Advanced Breast Cancer Progressing to ET and CDK4/6i.

ESR1 mutation MedSIR everolimus, elacestrant, Auxiliary Medicinal Product - Luteinizing hormone-releasing hormone (LHRH) analo NCT06382948

SHR-A1904 Compared With Investigator's Choice of Therapy in Claudin18.2 Positive Patitens With Second-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

Claudin 18.2 expression Jiangsu Hengrui SHR-A1904 NCT06649292

Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer

MSI-H / dMMR National Cancer Institute (NCI) durvalumab NCT04628767

Osimertinib to Suppress the Progression of GGN(EGFR Mutation-positive)

EGFR exon 19 deletion / L858R Samsung Medical Center osimertinib NCT04591002

Osimertinib to Suppress the Progression of Remaining GGN for EGFR Mutation-positive Stage IB-IIIA Lung Adenocarcinoma

EGFR exon 19 deletion / L858R Samsung Medical Center osimertinib NCT05528458

A Study to Assess the Efficacy of WSD0922-FU in Patients With C797S+ Advanced Non-small Cell Lung Cancer

EGFR exon 19 deletion / L858R Wayshine Biopharm WSD0922 NCT06868485

Study of Osimertinib and Stereotactic Ablative Radiation (SABR) in EGFR Mutant NSCLC

EGFR exon 19 deletion / L858R University of Texas Southwestern Medical Center osimertinib NCT03667820

Trastuzumab Deruxtecan (T-DXd) for People With Brain Cancer

EGFR exon 20 insertionHER2 (ERBB2) activating mutationHER2-low / ultralow (IHC 1+ or 2+/ISH-) Memorial Sloan Kettering Cancer Center trastuzumab deruxtecan NCT06058988

Glecirasib Combined With Ivonescimab for First-line Treatment of KRAS G12C-mutated NSCLC

KRAS G12C Cancer Institute and Hospital, Chinese Academy of Medical Sciences glecirasib, ivonescimab NCT07339839

IBI351 Plus Cetuximab β in Untreated Advanced Non-small Cell Lung Cancer With KRAS G12C Mutation

KRAS G12C Guangdong Association of Clinical Trials fulzerasib, cetuximab NCT07198841

GH21 Combined With D-1553 in KRAS G12C Mutant Advanced Solid Tumors

KRAS G12C Suzhou Genhouse Bio GH21, garsorasib NCT06435455

A Single-Arm, Open-Label, Multicenter Phase I/II Clinical Study of GFH276 in Patients With RAS-Mutant Advanced Solid Tumors

KRAS G12CKRAS G12D Genfleet Therapeutics GFH276 NCT07198321

Study Investigating ASP3082 in Patients With Metastatic/Locally Advanced Non-small-cell Lung Cancer (NSCLC) and Pancreatic Ductal Adenocarcinoma (PDAC), With Biomarker Analysis to Characterize Response/Resistance

KRAS G12D Gustave Roussy, Cancer Campus, Grand Paris setidegrasib NCT07483983

A Study of Vemurafenib and Obinutuzumab Compared to Cladribine and Rituximab in People With Hairy Cell Leukemia (HCL)

BRAF V600E Memorial Sloan Kettering Cancer Center vemurafenib, Obinutuzumab, rituximab NCT06561360

Treatment of BRAF ( B-Rapidly Accelerated Fibrosarcoma) Mutated Papillary Craniopharyngioma

BRAF V600E Eva Marie Erfurth, MD, PhD dabrafenib, trametinib NCT05525273

A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer

BRAF V600E Iovance Biotherapeutics IOV-4001 NCT05361174

PDR001 Combination Therapy for Radioiodine-Refractory Thyroid Cancer

BRAF V600E Memorial Sloan Kettering Cancer Center trametinib, dabrafenib, spartalizumab NCT04544111

Dabrafenib Combined With Trametinib After Radiation Therapy in Treating Patients With Newly-Diagnosed High-Grade Glioma

BRAF V600E National Cancer Institute (NCI) dabrafenib, trametinib NCT03919071

VISTA: Valproic Acid, Irinotecan, and Simvastatin for Recurrent Glioma

IDH1/2 mutation Inova Health Care Services Valproic Acid (VPA), Simvastatin NCT07831369

IDH Targeted/Non- Targeted vs Non-targeted/IDH-targeted Approaches in the Treatment of Newly Diagnosed IDH Mutated AML Patients Not Candidates for Intensive Induction Therapy (I- DATA Study)

IDH1/2 mutation Alice Mims enasidenib, ivosidenib, venetoclax NCT05401097

Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies

IDH1/2 mutation M.D. Anderson Cancer Center ivosidenib, venetoclax NCT03471260

Enasidenib and Azacitidine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia and IDH2 Gene Mutation

IDH1/2 mutation M.D. Anderson Cancer Center enasidenib NCT03683433

Venetoclax in Association With 3+7 and Midostaurin in FLT3-mutated Acute Myeloid Leukemia

FLT3 mutation (ITD/TKD) University Hospital, Bordeaux venetoclax, midostaurin NCT07726576

Bozitinib Combined With Chemotherapy as Radical Treatment for Stage IIA-IIIC MET-Altered Non-Small Cell Lung Cancer

MET exon 14 skipping Shanghai Pulmonary Hospital, Shanghai vebreltinib NCT07153770

Vebreltinib for Neoadjuvant in METex 14 Skipping Mutant Stage IIA-IIIB (N2) Non-small Cell Lung Cancer (NSCLC)

MET exon 14 skipping Fudan University vebreltinib NCT07156604

A Study of Lirafugratinib in Non-CCA Solid Tumors With FGFR2 Fusion or Rearrangement

FGFR2 fusion or rearrangement Elevar Therapeutics lirafugratinib NCT07359820

T-DXd With or Without Bevacizumab for HER2-low Breast Cancer With Brain Metastasis

HER2-low / ultralow (IHC 1+ or 2+/ISH-) Fudan University bevacizumab, trastuzumab deruxtecan NCT07150208

Dose-Expansion Modular Study To Explore the Safety, Tolerability, and Anti-tumor Activity of HER3- DXd Monotherapy and Combinations in Patients With Inoperable Advanced Breast Cancer (ABC) After Progression on T-DXd

HER2-low / ultralow (IHC 1+ or 2+/ISH-) Gustave Roussy, Cancer Campus, Grand Paris patritumab deruxtecan, olaparib NCT06298084

A Phase Ib/II Study of ATG-022 Plus Pembrolizumab With/Without Chemotherapy in Participants With Claudin (CLDN) 18.2-positive, HER2-negative, Unresectable or Metastatic Gastric or Gastroesophageal Junction AdenocarcinomaUnresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

Claudin 18.2 expression Antengene Biologics ATG-022, pembrolizumab NCT07327229

Testing Ivonescimab in Combination With Chemotherapy in Advanced or Metastatic Gastric/Gastroesophageal Adenocarcinoma

Claudin 18.2 expression UNICANCER ivonescimab NCT06846346

A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors

MSI-H / dMMR Marengo Therapeutics STAR0602 NCT05592626

Safety and Efficacy of PD-1 ± mFOLFOX6 Neoadjuvant Therapy in Local Advanced sMPCC

MSI-H / dMMR Sixth Affiliated Hospital, Sun Yat-sen University All-MSI-H (dMMR) sMPCC: single-drug PD-1 monoclonal antibody neoadjuvant therapy NCT06002789

An Open-label Phase 3b Study of Ivosidenib in Combination With Azacitidine in Adult Patients Newly Diagnosed With IDH1m Acute Myeloid Leukemia (AML) Ineligible for Intensive Induction Chemotherapy.

IDH1/2 mutation Servier Affaires Médicales ivosidenib NCT05907057

Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer

HER2-low / ultralow (IHC 1+ or 2+/ISH-) Daiichi Sankyo trastuzumab deruxtecan, trastuzumab NCT05950945

JS107 vs Investigator's Choice as Second-line or Later Therapy for Advanced CLDN18.2-Positive Gastricor GEJ Adenocarcinoma.

Claudin 18.2 expression Shanghai Junshi Bioscience JS107 for Injection NCT07284134

A Study to Investigate Safety and Efficacy of Osimertinib and Amivantamab in Participants With Non-small Cell Lung Cancer With Common Epidermal Growth Factor Receptor Mutations

EGFR exon 19 deletion / L858R AstraZeneca osimertinib, amivantamab NCT05801029

A Phase II Study of Neoadjuvant Sotorasib in Combination With Cisplatin or Carboplatin and Pemetrexed for Surgically Resectable Stage IIA-IIIB Non-Squamous Non-Small Cell Lung Cancer With a KRAS p.G12C Mutation

KRAS G12CKRAS G12D M.D. Anderson Cancer Center sotorasib NCT05118854

Preventing High Blood Sugar in People Being Treated for Metastatic Breast Cancer

PIK3CA activating mutation Memorial Sloan Kettering Cancer Center alpelisib, fulvestrant, Canagliflozin NCT05090358

A Study of Disitamab Vedotin in Adults With HER2 Expressing Advanced Breast Cancer

BRCA1/2 mutationHER2-low / ultralow (IHC 1+ or 2+/ISH-) Pfizer disitamab vedotin NCT06966453

Study of TROP2 CAR Engineered IL15-transduced Cord Blood-derived NK Cells Delivered Intraperitoneally for the Management of Platinum Resistant Ovarian Cancer, Mesonephric-like Adenocarcinoma, and Pancreatic Cancer

BRCA1/2 mutation M.D. Anderson Cancer Center TROP2-CAR-NK NCT05922930

Venetoclax in Combination With Cladribine and Cytarabine Alternating With Azacitidine Plus Venetoclax for the Treatment of Newly Diagnosed Monocytic AML and Active Signaling Mutated AML

FLT3 mutation (ITD/TKD) OHSU Knight Cancer Institute venetoclax NCT06504459

A Phase I/II Study of Gilteritinib and Momelotinib for Patients With Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia

FLT3 mutation (ITD/TKD) M.D. Anderson Cancer Center gilteritinib, Momelotinib NCT06235801

Allo HSCT Using RIC and PTCy for Hematological Diseases

NPM1 mutation Masonic Cancer Center, University of Minnesota Peripheral Blood Stem Cell Transplant, Allopurinol 300 MG, Bone Marrow Cell Transplant, Sirolimus Pill NCT05805605

TQB2450 Plus Progestin for Fertility-sparing Treatment in MMRd EC

MSI-H / dMMR Fudan University benmelstobart NCT06914297

A Study of Dostarlimab in Participants With Untreated Locally Advanced Rectal Cancer in China

MSI-H / dMMR GSK dostarlimab NCT06640049